Explore more publications!

Latest News

Labels On
FILTER THE FEED
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate
FILTER THE FEED
Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Kallyope’s migraine drug advances to pivotal trial

Kallyope’s migraine drug advances to pivotal trial

Indeterminate Clinical Trials Arena
Owner: Michael "Mike" Danson
<![CDATA[Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis]]>

<![CDATA[Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis]]>

Indeterminate HCPLive
Owner: Mike Hennessy Jr.
Business News | Unveiling the Dark Secrets of the Pharmaceutical Industry: Nivin Pauly's Pharma Trailer Promises High-Stakes, Strong Content

Business News | Unveiling the Dark Secrets of the Pharmaceutical Industry: Nivin Pauly's Pharma Trailer Promises High-Stakes, Strong Content

Telangana government inks MoUs with pharma companies for investments of ₹9,500 cr

Telangana government inks MoUs with pharma companies for investments of ₹9,500 cr

Indian or MNC pharma companies? There are reasons to look at both: 5 pharma stocks with upside potential of up to 38%

Indian or MNC pharma companies? There are reasons to look at both: 5 pharma stocks with upside potential of up to 38%

Comorbidities Are Driving Up Healthcare Costs — Here’s How More Specialized Care Management Can Bring Them Under Control

Comorbidities Are Driving Up Healthcare Costs — Here’s How More Specialized Care Management Can Bring Them Under Control

Big drama over Big Pharma: McKee still linking Foulkes to opioid...

Big drama over Big Pharma: McKee still linking Foulkes to opioid...

ASH 2025: MSD’s B-ALL drug shows potential, but all patients experience AEs

ASH 2025: MSD’s B-ALL drug shows potential, but all patients experience AEs

Insilico Details AI-Designed, Cancer-Fighting PROTAC Targeting PKMYT1

Insilico Details AI-Designed, Cancer-Fighting PROTAC Targeting PKMYT1

The Exec: How to Engage Physicians in Quality, Cost Reduction, and Value-Based Care

The Exec: How to Engage Physicians in Quality, Cost Reduction, and Value-Based Care

<![CDATA[An Impressive Year: Looking Back on Our 40th Anniversary]]>

<![CDATA[An Impressive Year: Looking Back on Our 40th Anniversary]]>

Indeterminate Psychiatric Times - New Jersey
Owner: Mike Hennessy Jr.
<![CDATA[FDA selects detalimogene for manufacturing readiness program]]>

<![CDATA[FDA selects detalimogene for manufacturing readiness program]]>

Indeterminate Urology Times
Owner: Mike Hennessy Jr.
<![CDATA[Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA]]>

<![CDATA[Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA]]>

Indeterminate HCPLive
Owner: Mike Hennessy Jr.
<![CDATA[NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia]]>

<![CDATA[NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia]]>

Indeterminate Psychiatric Times - New Jersey
Owner: Mike Hennessy Jr.
Business News | Unveiling the Dark Secrets of the Pharmaceutical Industry: Nivin Pauly's Pharma Trailer Promises High-Stakes, Strong Content

Business News | Unveiling the Dark Secrets of the Pharmaceutical Industry: Nivin Pauly's Pharma Trailer Promises High-Stakes, Strong Content

Telangana government inks MoUs with pharma companies for investments of ₹9,500 cr

Telangana government inks MoUs with pharma companies for investments of ₹9,500 cr

Indian or MNC pharma companies? There are reasons to look at both: 5 pharma stocks with upside potential of up to 38%

Indian or MNC pharma companies? There are reasons to look at both: 5 pharma stocks with upside potential of up to 38%

Comorbidities Are Driving Up Healthcare Costs — Here’s How More Specialized Care Management Can Bring Them Under Control

Comorbidities Are Driving Up Healthcare Costs — Here’s How More Specialized Care Management Can Bring Them Under Control

Big drama over Big Pharma: McKee still linking Foulkes to opioid...

Big drama over Big Pharma: McKee still linking Foulkes to opioid...

ASH 2025: MSD’s B-ALL drug shows potential, but all patients experience AEs

ASH 2025: MSD’s B-ALL drug shows potential, but all patients experience AEs

Insilico Details AI-Designed, Cancer-Fighting PROTAC Targeting PKMYT1

Insilico Details AI-Designed, Cancer-Fighting PROTAC Targeting PKMYT1

The Exec: How to Engage Physicians in Quality, Cost Reduction, and Value-Based Care

The Exec: How to Engage Physicians in Quality, Cost Reduction, and Value-Based Care

<![CDATA[An Impressive Year: Looking Back on Our 40th Anniversary]]>

<![CDATA[An Impressive Year: Looking Back on Our 40th Anniversary]]>

<![CDATA[FDA selects detalimogene for manufacturing readiness program]]>

<![CDATA[FDA selects detalimogene for manufacturing readiness program]]>

<![CDATA[Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA]]>

<![CDATA[Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA]]>

<![CDATA[NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia]]>

<![CDATA[NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia]]>

Kallyope’s migraine drug advances to pivotal trial

Kallyope’s migraine drug advances to pivotal trial

<![CDATA[Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis]]>

<![CDATA[Dupilumab Superior in Analysis of Monoclonal Antibodies for Atopic Dermatitis]]>

Show More

Video Stories

YouTube video thumbnail: Why Native Americans are Facing High Rates of Mental Decline
Play
Why Native Americans are Facing High Rates of Mental Decline
YouTube video thumbnail: Revolutionary Gene Therapy Brings Hope of Leukaemia Cure
Play
Revolutionary Gene Therapy Brings Hope of Leukaemia Cure
YouTube video thumbnail: Australian Clinic Tackles Screen Addiction as Social Media Ban Looms
Play
Australian Clinic Tackles Screen Addiction as Social Media Ban Looms
YouTube video thumbnail: Croatians Turn to Cold Plunges to Boost Health. Are Near-Freezing Swims Good for you?
Play
Croatians Turn to Cold Plunges to Boost Health. Are Near-Freezing Swims Good for you?

Video Title

Press Releases

RCP president and resident doctors write to The Times with call for urgent action on training bottlenecks

RCP president and resident doctors write to The Times with call for urgent action on training bottlenecks

Clarity, not caricature, must lead the mental health debate

Clarity, not caricature, must lead the mental health debate

The Re-Emergence of Contingent Value Rights

The Re-Emergence of Contingent Value Rights

Attor­ney Gen­er­al Pax­ton Sues Big Phar­ma Com­pa­nies Bris­tol-Myers Squibb and Sanofi for Mak­ing Bil­lions While Harm­ing Amer­i­cans and Fail­ing to Dis­close Plavix’s Ineffectiveness

Attor­ney Gen­er­al Pax­ton Sues Big Phar­ma Com­pa­nies Bris­tol-Myers Squibb and Sanofi for Mak­ing Bil­lions While Harm­ing Amer­i­cans and Fail­ing to Dis­close Plavix’s Ineffectiveness

RCP president and resident doctors write to The Times with call for urgent action on training bottlenecks

RCP president and resident doctors write to The Times with call for urgent action on training bottlenecks

Clarity, not caricature, must lead the mental health debate

Clarity, not caricature, must lead the mental health debate

The Re-Emergence of Contingent Value Rights

The Re-Emergence of Contingent Value Rights

Attor­ney Gen­er­al Pax­ton Sues Big Phar­ma Com­pa­nies Bris­tol-Myers Squibb and Sanofi for Mak­ing Bil­lions While Harm­ing Amer­i­cans and Fail­ing to Dis­close Plavix’s Ineffectiveness

Attor­ney Gen­er­al Pax­ton Sues Big Phar­ma Com­pa­nies Bris­tol-Myers Squibb and Sanofi for Mak­ing Bil­lions While Harm­ing Amer­i­cans and Fail­ing to Dis­close Plavix’s Ineffectiveness

Show More
Your brand’s story is being written — with or without you.
We’re the leading press release service for mid-sized businesses & organizations built for the AI era.
Learn more

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions